Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.36 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.36 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7218922 | 0.98 | BLM (0.38) | TSHRSLC6A1SLC6A13GABRPGABRD | |
| SCHEMBL1286825 | 0.65 | TSHR (0.40) | TSHRSLC6A1SLC6A13GABRPGABRD | |
| SCHEMBL8993949 | 0.64 | — | — | |
| SCHEMBL2301074 | 0.62 | — | — | |
| SCHEMBL5912729 | 0.62 | — | — | |
| SCHEMBL1355416 | 0.62 | TSHR (0.42) | TSHRSLC6A1SLC6A13GABRPGABRD | |
| SCHEMBL6544012 | 0.62 | GABRP (0.33) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL1812431 | 0.62 | TSHR (0.33) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL17597680 | 0.61 | BLM (0.41) | TSHRSLC6A1SLC6A13GABRPGABRD | |
| SCHEMBL7648980 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12233053-B2 | Adenosine A3 receptor antagonists for treating aging skin and wounds | ORADIN PHARMACEUTICAL LTD. (IL) | 2025-02-25 | — | — | US | claimed |
| CN-114200499-A | Method for detecting irradiation dose distribution and irradiation-resistant composition | 上海珀利医用材料有限公司 | 2022-03-18 | — | — | CN | claimed |
| EP-2229167-A1 | MINERALOCORTICOID RECEPTOR MODULATORS | Merck Sharp & Dohme Corp. (US) | 2010-09-22 | — | — | EP | claimed |
| WO-2009078934-A1 | MINERALOCORTICOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2009-06-25 | — | — | WO | claimed |
| EP-0225175-A2 | Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof | FISONS plc (GB) | 1987-06-10 | — | — | EP | claimed |
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-20250101104-A1 | BISPECIFIC MOLECULE WITH TUNABLE AFFINITY TO A TARGETED ANTIGEN | MABSWITCH INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240139205-A1 | MODULATORS OF ARALAR FOR TREATING NEUROLOGICAL DISORDERS | UNIVERSITE DE LAUSANNE (CH) | 2024-05-02 | — | — | US | disclosed |
| WO-2024069007-A2 | IMMUNOSUPPRESSIVE COMPOUNDS | UNIVERSITÄT BASEL (CH) | 2024-04-04 | — | — | WO | disclosed |
| US-20230330126-A1 | MODIFIED ADENOSINE NUCLEOSIDE FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | IACHETTINI GIAMPIETRO (IT) | 2023-10-19 | — | — | US | disclosed |
| EP-0371492-A2 | Process for the preparation of 1,4-dihydropyridine derivatives | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1990-06-06 | — | — | EP | disclosed |
| EP-0324626-A1 | 1,4-Dihydropyridine derivatives | Korea Research Institute of Chemical Technology (KR) | 1989-07-19 | — | — | EP | disclosed |
| US-4769465-A | Process for the preparation of 2-(N-benzyl-N-methylamino)-ethyl methyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate and its hydrochloride salt | LEK, TOVARNA FARMACEVTSKIH IN KEMICNIH IZDELKOV, N.SOL.O. (YU) | 1988-09-06 | — | — | US | disclosed |
| US-4637887-A | TRIGLYCERIDES CONTAINING HYDROXY FATTY ACID RESIDUES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1987-01-20 | — | — | US | disclosed |
| EP-0197488-A2 | 1,4-Dihydropyiridine derivative, a process for preparing the same, a pharmaceutical composition as well as the use thereof | Eisai Co., Ltd. (JP) | 1986-10-15 | — | — | EP | disclosed |
| EP-0161877-A2 | 1,4-dihydropyridine derivatives, methods for their production and pharmaceutical compositions comprising the same | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) | 1985-11-21 | — | — | EP | disclosed |
| US-4483985-A | ALKALINE HYDROLYSIS OF ESTER GROUP | BAYER AKTIENGESELLSCHAFT (DE) | 1984-11-20 | — | — | US | disclosed |
| US-4285955-A | CARDIOTONIC, HYPOTENSIVE, AND ANTISPASMOTIC AGENTS; VASODILATION | BAYER AKTIENGESELLSCHAFT (DE) | 1981-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN8A, SCN1B, SCN3A | TSHR 1088/4885SLC6A1 198/4885SLC6A13 475/4885 |
| US-20240139205-A1 | MODULATORS OF ARALAR FOR TREATING NEUROLOGICAL DISORDERS | CYFIP1, GABARAPL1, GABRR1 | TSHR 4071/4885SLC6A1 211/4885SLC6A13 220/4885 |
| US-20230330126-A1 | MODIFIED ADENOSINE NUCLEOSIDE FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | ADORA2A, ADORA3, ADORA2B | TSHR 1545/4885SLC6A1 4673/4885SLC6A13 4430/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | TSHR 895/4885SLC6A1 4503/4885SLC6A13 4526/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | TSHR 1094/4885SLC6A1 4853/4885SLC6A13 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.